Physician profile
Saul Ramirez
NPI 1043881691
$6,459.23
in general payments reported to CMS, 2019-2025
33 companies · $3,561 in 2025
The $3,561 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $591 · 2024: $2,307 · 2025: $3,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,056.18 | 2023-2025 | Farxiga, Airsupra, Saphnelo |
| Novo Nordisk INC | $661.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $545.31 | 2023-2025 | Mounjaro, Kisunla, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.45 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $489.03 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $404.32 | 2023-2025 | |
| Amgen INC. | $344.20 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $325.39 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $310.69 | 2023-2025 | Verquvo, Belsomra, Vaxneuvance |
| Exact Sciences Corporation | $230.10 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Corcept Therapeutics | $197.25 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $146.19 | 2024 | Xarelto |
| Axsome Therapeutics, INC. | $140.61 | 2025 | Sunosi |
| Neurocrine Biosciences, INC. | $139.93 | 2025 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.66 | 2024-2025 | |
| Ardelyx, INC. | $119.18 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $83.54 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lexicon Pharmaceuticals, INC. | $73.09 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $62.28 | 2024-2025 | Zoryve |
| Mylan Specialty L.P. | $57.61 | 2024 | Yupelri |
| Shield Therapeutics INC | $54.55 | 2025 | |
| Sanofi-Aventis U.S. LLC | $45.64 | 2024-2025 | |
| Abiomed | $36.63 | 2025 | |
| Astellas Pharma US INC | $32.75 | 2024 | Veozah |
| Averitas Pharma INC. | $28.29 | 2025 | Qutenza |
| Ethicon US, LLC | $26.27 | 2025 | Harmonic |
| Actelion Pharmaceuticals US, INC. | $20.84 | 2024 | Opsumit |
| Sanofi Pasteur INC. | $20.43 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.04 | 2023 | Xifaxan |
| Dexcom, INC. | $17.66 | 2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $17.14 | 2024 | |
| Cequr Corporation | $9.57 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.